Table 3.
Subsequent systemic treatments after progression on palbociclib classified by pharmacological classes.
| Number | |
|---|---|
| Subsequent chemotherapy (n = 147, 73.5%) | |
| Monotherapy (n = 76) | |
| Nab-paclitaxel/paclitaxel/docetaxel | 29 |
| Capecitabine | 21 |
| Vinorelbine | 17 |
| Liposomal doxorubicin | 5 |
| Eribulin | 2 |
| Cyclophosphamide | 2 |
| Combined with anti-VEGFR (n = 17) (bevacizumab or apatinib) | |
| + Nab-paclitaxel/paclitaxel | 15 |
| + Capecitabine | 1 |
| + Eribulin | 1 |
| Combined with other chemotherapy agents (n = 54) | |
| Taxane-based (n = 37) | |
| Vinorelbine+capecitabine (n = 13) | |
| Liposomal doxorubicin-based (n = 4) | |
| Subsequent endocrine therapy (n = 53, 26.5%) | |
| Monotherapy (n = 7) | |
| Fulvestrant | 4 |
| Exemestane | 2 |
| Anastrozole | 1 |
| Combined with target agents (n = 46) | |
| Chidamide-based (n = 21) | |
| + Exemestane | 16 |
| + Tamoxifen | 3 |
| + Fulvestrant | 1 |
| + Anastrozole | 1 |
| Everolimus-based (n = 15) | |
| + Exemestane | 9 |
| + Fulvestrant | 3 |
| + Letrozole | 1 |
| + Anastrozole | 1 |
| + Toremifene | 1 |
| Palbociclib-based (n = 10) | |
| + Fulvestrant | 3 |
| + Anastrozole | 3 |
| + Exemestane | 2 |
| + Toremifene | 2 |
VEGFR, anti-vascular endothelial growth factor receptor.